Last reviewed · How we verify
Elranatamab injection — Competitive Intelligence Brief
phase 2
Bispecific antibody
Live · refreshed every 30 min
Target snapshot
Elranatamab injection (elranatamab-injection) — Pfizer Inc..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Elranatamab injection TARGET | elranatamab-injection | Pfizer Inc. | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Elranatamab injection CI watch — RSS
- Elranatamab injection CI watch — Atom
- Elranatamab injection CI watch — JSON
- Elranatamab injection alone — RSS
Cite this brief
Drug Landscape (2026). Elranatamab injection — Competitive Intelligence Brief. https://druglandscape.com/ci/elranatamab-injection. Accessed 2026-05-14.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab